Search

Displaying results 3211 - 3220 of 6951 in total
  1. Drug

    Pentastarch

    go.drugbank.com/drugs/DB09111
    ApprovedWithdrawn

    It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation.

  2. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [L47122] In June 2023, Rozanolixizumab-noli was approved by the FDA under Priority Review for the treatment of adult patients with generalized myasthenia gravis who are positive for the anti-acetylcholine … [A260177] It is investigated for use in autoimmune and alloimmune diseases with pathologic IgG, particularly generalized myasthenia gravis.

    Categories: Neonatal Fc Receptor Blocker
  3. Target

    Translocator protein

    go.drugbank.com/bio_entities/BE0000736
    TargetHumans

    Was initially identified as peripheral-type benzodiazepine receptor; can also bind isoquinoline carboxamides (PubMed:1847678)

    Synonyms: Mitochondrial benzodiazepine receptor, Peripheral-type benzodiazepine receptor
  4. Drug

    Tasimelteon

    go.drugbank.com/drugs/DB09071
    ApprovedInvestigational

    Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). … Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.

    Categories: Melatonin Receptor Agonists
  5. Drug

    ISIS 113715

    go.drugbank.com/drugs/DB05506
    Investigational

    ISIS 113715 is our second-generation antisense inhibitor of protein tyrosine phosphatase 1b, or PTP‑1b, for the treatment of type 2 diabetes.

  6. Drug

    Dexamethasone acetate

    go.drugbank.com/drugs/DB14649
    ApprovedInvestigationalVet approved

    Dexamethasone was therefore recommended as a life-saving treatment for COVID-19 patients experiencing severe respiratory symptoms.[L14318] … [A188724] Dexamethasone acetate has largely been replaced by [dexamethasone] phosphate and continues to be administered for a large variety of inflammatory conditions.

  7. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    antagonizes the overactive fibroblast growth factor receptor 3 (FGFR3) signaling pathway responsible for impaired bone growth in individuals with achondroplasia. … [L56065] Navepegritide was approved by the US FDA in February 2026 for use in patients 2 years of age and older with achondroplasia with open epiphyses.[L56058,L56065]

  8. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. … [A225916] Currently available treatments for end-stage renal disease are limited to dialysis and renal transplantation, with the former associated with significant costs and lower quality of life.

  9. Drug

    BNT162a1 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15697
    Experimental

    [L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    BNT162c2 SARS-CoV-2 Vaccine

    go.drugbank.com/drugs/DB15698
    Experimental

    [L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.

    Categories: Experimental Unapproved Treatments for COVID-19